ArticleBlood advances2025

Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.

Jia Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.